MedTrace Logo

Evaluation of the Immunopharmacology of EDP1815 and EDP2939

NCT05682222 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2023-05-19

No results posted yet for this study

Summary

A single-center, randomized, double-blind, placebo-controlled, multiple dose platform trial.

Conditions

  • KLH and Imiquimod Induced Skin Inflammation in Healthy Volunteers

Interventions

DRUG

EDP1815

EDP1815 is an essentially non-viable, non-replicating pharmaceutical preparation of a single strain of Prevotella histicola, a naturally occurring human commensal microbe.

DRUG

EDP2939

EDP2939 is a pharmaceutical preparation of extracellular vesicles.

DRUG

Placebo oral capsule

Placebo.

Sponsors & Collaborators

  • Evelo Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-27
Primary Completion
2022-10-14
Completion
2022-10-14

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05682222 on ClinicalTrials.gov